These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20527756)

  • 1. Pharmaceutical perspectives of nonlinear QSAR strategies.
    Michielan L; Moro S
    J Chem Inf Model; 2010 Jun; 50(6):961-78. PubMed ID: 20527756
    [No Abstract]   [Full Text] [Related]  

  • 2. Quo vadis, virtual screening? A comprehensive survey of prospective applications.
    Ripphausen P; Nisius B; Peltason L; Bajorath J
    J Med Chem; 2010 Dec; 53(24):8461-7. PubMed ID: 20929257
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular fields in drug discovery: getting old or reaching maturity?
    Cross S; Cruciani G
    Drug Discov Today; 2010 Jan; 15(1-2):23-32. PubMed ID: 19150413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework?
    Dobchev D; Karelson M
    Expert Opin Drug Discov; 2016 Jul; 11(7):627-39. PubMed ID: 27149299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoinformatics-applications in food chemistry.
    Martinez-Mayorga K; Medina-Franco JL
    Adv Food Nutr Res; 2009; 58():33-56. PubMed ID: 19878857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ionization-specific QSAR models of blood-brain penetration of drugs.
    Lanevskij K; Japertas P; Didziapetris R; Petrauskas A
    Chem Biodivers; 2009 Nov; 6(11):2050-4. PubMed ID: 19937840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
    Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
    J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of antibacterial compounds by machine learning approaches.
    Yang XG; Chen D; Wang M; Xue Y; Chen YZ
    J Comput Chem; 2009 Jun; 30(8):1202-11. PubMed ID: 18988254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison data sets for benchmarking QSAR methodologies in lead optimization.
    Mittal RR; McKinnon RA; Sorich MJ
    J Chem Inf Model; 2009 Jul; 49(7):1810-20. PubMed ID: 19569715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
    Korfmacher W
    Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
    [No Abstract]   [Full Text] [Related]  

  • 12. Free versus total ligand-binding assays: points to consider in biotherapeutic drug development.
    Yang J; Quarmby V
    Bioanalysis; 2011 Jun; 3(11):1163-5. PubMed ID: 21649490
    [No Abstract]   [Full Text] [Related]  

  • 13. QSAR modeling of the inhibition of glycogen synthase kinase-3.
    Katritzky AR; Pacureanu LM; Dobchev DA; Fara DC; Duchowicz PR; Karelson M
    Bioorg Med Chem; 2006 Jul; 14(14):4987-5002. PubMed ID: 16650999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
    Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
    J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational toxicology in drug development.
    Muster W; Breidenbach A; Fischer H; Kirchner S; Müller L; Pähler A
    Drug Discov Today; 2008 Apr; 13(7-8):303-10. PubMed ID: 18405842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of linear, ensemble, and nonlinear models for the prediction and interpretation of the biological activity of a set of PDGFR inhibitors.
    Guha R; Jurs PC
    J Chem Inf Comput Sci; 2004; 44(6):2179-89. PubMed ID: 15554688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.
    Kruhlak NL; Contrera JF; Benz RD; Matthews EJ
    Adv Drug Deliv Rev; 2007 Jan; 59(1):43-55. PubMed ID: 17229485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting QSAR models in lead optimization.
    Gedeck P; Lewis RA
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):569-75. PubMed ID: 18600573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites.
    Schmidtke P; Barril X
    J Med Chem; 2010 Aug; 53(15):5858-67. PubMed ID: 20684613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.